To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Evotec OAI Signs Medicinal Chemistry Agreement with Axxima Pharmaceuticals
25-06-2003: Evotec OAI, a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and Axxima Pharmaceuticals AG, a drug discovery and development company leading the field of pathogen-host signal transduction, today announced that they have entered into a medicinal chemistry agreement to design and synthesise small molecule lead structures for one of Axxima(TM)s leading kinase targets.
Under the terms of the drug discovery contract Evotec OAI will apply its integrated medicinal chemistry platform to optimise initial screening hits already identified by Axxima and rapidly progress them towards novel clinical candidates for clinical trials. Financial details of the collaboration were not disclosed.
"Signing this contract with Axxima is a further strong validation of the quality of our integrated medicinal chemistry offering," said Jörn Aldag, President and Chief Executive Officer of Evotec OAI. "We are delighted that Axxima chose us to support them in building strong intellectual property around one of their anti-infective targets."
"The chemistry expertise provided by Evotec OAI ideally complements our in-house medicinal chemistry programs," said Dr. Gerhard Müller, Chief Scientific Officer of Axxima. "The professionalism of their integrated medicinal chemistry platform qualifies Evotec OAI as an ideal long-term drug discovery partner to support us in progressing selected projects into promising clinical drug candidates."
This is where you can add this news to your personal favourites
- 1Drew Industrial Division of Ashland Specialty Chemical Company purchases industrial water-treatment business of London-based Fer
- 2Allegra® Launched in Japan
- 3LG-DOW Polycarbonate Plant Starts Production in Korea to Effectively Meet Regional Needs
- 4Putting electronic cigarettes to the test
- 5Honeywell Appoints Terrence Hahn as Vice President and General Manager for Fluorine Products
- 6Caflon® surfactants from Univar as substitutes for banned nonylphenol ethoxylates
- 7Not just cars, but living organisms need antifreeze to survive
- 8Plurafac LF 303 - Plurafac LF 305: The new generation of low-foam surfactants
- 9Knoll AG: Pharma business sold for $6.9 billion:
- 10Stockhausen, a subsidiary of Degussa, develops a special product for de-inking and de-watering of sludge
- BASF strengthens its enzyme technology footprint
- Membrane elements from LANXESS approved for drinking water applications
- A new laser paradigm: An electrically injected polariton laser
- Biesterfeld establishes branch office in Thailand
- UC Santa Barbara scientist studies methane levels in cross-continent drive